1 - 15 of 15
Dr. Bagatell’s research focuses on improving therapies for children with neuroblastoma. She leads clinical research studies designed to critically evaluate current therapies for children with high-risk and relapsed disease, and is committed to conducting studies of new therapies for this population. She is currently pursuing research designed to evaluate biomarkers for response to targeted therapy in children with high-risk disease.
Dr. Barakat's research is focused on examining risk-and-resilience models to characterize disease management and health-related quality of life of children with chronic health conditions and their families. Another focus of investigation is translation of these models into evidence-based assessment (family psychosocial risk screening) as well as family-based, mHealth interventions to improve disease management and to support medical decision-making for youth with cancer and their families.
Dr. Barret's research program focuses on immune function of children with cancer. His research involves investigating possible immune deficiencies that result in children developing cancer and developing immune-based therapies for childhood cancer.
Dr. Bassing's research program focuses on the genetic, epigenetic, and biochemical mechanisms by which mammals develop their immune systems while suppressing autoimmunity and genomic aberrations that cause leukemia or lymphoma.
The cure rate for children with neuroblastoma is unacceptable, making it imperative that new therapies are developed. Dr. Bosse's laboratory is focused on discovering and developing new neuroblastoma cell surface immunotherapeutic targets. Along with his colleagues, Dr. Bosse's aim is to capitalize on the robust differential expression of these molecules with immune-based therapies and also define their mechanisms of overexpression and roles in tumorigenesis.
Dr. Broedur’s research interests focus on nanoparticle drug delivery and cancer predisposition. He is also interested in identifying novel cancer predisposition genes, and developing enhanced surveillance techniques to identify cancer early in predisposed individuals with the hope of improving outcome and reducing side effects.